A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
- Conditions
- Parkinson DiseaseDementia
- Interventions
- Drug: Active Investigational Treatment ENT-01
- Registration Number
- NCT03938922
- Lead Sponsor
- Enterin Inc.
- Brief Summary
This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.
- Detailed Description
The study will be conducted on an out-patient basis. Each patient will have 5 visits to the clinic: a screening visit, a randomization visit, 1 followup visit, 1 end of treatment visit, and 1 end of study visit.
Patients will be allowed to adjust their dosing, based upon protocol specifications. Rescue medications will be provided to all patients to ensure they move their bowels on a regular basis.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Patients aged 30-90 years, both genders
- Patients or care-giver must provide informed consent and be willing and able to comply with study procedures.
- Patients must be diagnosed with Parkinson's disease defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features: rest tremor, rigidity, bradykinesia and/or akinesia, postural and gait abnormalities.
- Patients must have dementia as defined by (1) decline in cognitive function and (2) functional impairment, which together in, in the opinion of the investigator, has resulted in a clinical diagnosis of dementia.
- MoCA < 24 in support of a dementia diagnosis
- Have a reliable and actively involved caregiver who must be able to communicate in English and be willing to comply with protocol requirements.
- If on anti-parkinsonian agents, participants must be on stable dosage for at least 4 weeks prior to baseline.
- If on medications enhancing cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 8 weeks prior to baseline.
- If on antidepressant medications, participants must be on stable dosage for at least 4 weeks prior to baseline.
- If on clozapine, pimavanserin or quetiapine to address drug-induced or disease-related psychosis, participants must be on stable dosage for 4 weeks prior to baseline.
- Female patients of childbearing potential must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.
- Female patients unable to bear children must have this documented in the case report form (CRF) (i.e., tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age.
- Patient or caregiver unable or unwilling to provide informed consent or to comply with study procedures.
- Unable to withdraw proton pump inhibitors at the end of run-in period.
- Unable to withdraw from anti-cholinergics at the beginning of the run-in period
- Any clinically significant abnormalities on screening laboratories or physical examination requiring further evaluation or treatment.
- Neurological disorder other than Parkinson's disease that in the opinion of the investigator might interfere with the conduct of the study
- Females who are pregnant or breastfeeding
- History of excessive alcohol use or substance abuse
- Psychotic disorder was present before the diagnosis of Parkinson's disease
- Patient or caregiver unable to administer daily oral dosing of study drug
- Caregiver unwilling or unable to unable to complete stool diary, dispense study medication and accompany the patient to all visits
- Participation in an investigational drug trial within the month prior to dosing in the present study.
- A compromised gastrointestinal system which includes: Structural, metabolic, or functional GI diseases or disorders; History of major GI surgery within 30 days (a history of cholecystectomy, polypectomy, hernia repair, appendicectomy, gastric surgery for peptic ulcer and gastric banding for obesity are not exclusionary as long as they were performed more than 30 days before the screening visit. Partial or complete colectomy is exclusionary).
- Review of Screening period diaries indicates either of the following: Fewer than 11 days of diary completion; More than 5 complete spontaneous bowel movements per week based upon the average Complete Spontaneous Bowel Movement (CSBM) rate reported during the Screening Period.
- Any other reason, which in the opinion of the investigator would confound proper interpretation of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Active Treatment Active Investigational Treatment ENT-01 ENT-01 tablet will be taken once daily by mouth.
- Primary Outcome Measures
Name Time Method Cognition Improvement by Dementia Severity Rating Scale (DSRS) - Primary Outcome 10 weeks To determine the safety and efficacy of repeated oral doses of ENT-01 in improving cognition in patients with Parkinson's disease dementia, measured by the Dementia Severity Rating Scale (DSRS).
The DSRS Test is used to track changes in cognitive status over time. Its five subscales provide additional information on specific abilities: Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory.
The score ranges from 0 to 54, with 0-18 being mild, 19-36 being moderate and 37-54 being severe. Improvements would be indicated by lower scores from baseline to end of fixed dose period.
- Secondary Outcome Measures
Name Time Method Change from Baseline in Montreal Cognitive Assessment (MOCA) - Secondary Outcomes 10 weeks To determine the effect of repeated oral doses of ENT-01 in improving cognition in patients with Parkinson's disease Dementia, measured by an improvement in the Montreal Cognitive Assessment (MOCA) from baseline.
Change from Baseline to the End of the Fixed Dose Period in Symptoms Adapted for Parkinson's Disease (SAPS-PD) - Secondary Outcomes 10 weeks To determine the effect of repeated oral doses of ENT-01 in improving the frequency and/or severity of hallucinations/delusions during the Fixed Dose period over baseline in patients with Parkinson's disease Dementia.
Improvement is defined as 2.33 points or greater reduction in score from baseline on the SAPS-PD.Change from Baseline to the End of the Fixed Dose Period in Neuropsychiatric Inventory (NPI) and Caregiver Distress (NPI-D) - Secondary Outcomes 10 weeks To determine the effect of repeated oral doses of ENT-01 in patients with Parkinson's disease Dementia, measured by an improvement in total score for behavioral impairment from baseline to the end of fixed dose for the NPI and NPI-D.
The NPI total score is calculated by adding the scores of the domains (each domain scores ranges from 0 to 144, with higher scores indicating greater behavioral impairment.
The caregiver distress scores in each of the domains are not included in the NPI total score. The caregiver distress (NPI-D) total score is calculated by adding scores of caregiver distress in each of the domains (score ranges from 0 to 5 in each domain). The NPID total score ranges from 0 to 60 with higher scores indicating greater distress.Change from Baseline to the End of the Fixed Dose Period in Parkinson's Disease Questionnaire-39 (PDQ-39) - Secondary Outcomes 10 weeks To determine the effect of repeated oral doses of ENT-01 in patients with Parkinson's disease Dementia, measured by an improvement in behavioral impairment, cognition, and social function by having lower scores for the PDQ-39 from baseline to the end of fixed dose.
The PDQ-39 assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication. Lower scores indicate better quality of life. There is a 5-point ordinal system for scoring - 0 is never, and 4 is always.
Trial Locations
- Locations (3)
Elias Research - Neurology Diagnostics Research
🇺🇸Dayton, Ohio, United States
Evolution Research Group - Neuroscience Research Institution
🇺🇸Toms River, New Jersey, United States
Neuro Pain Medical Center
🇺🇸Fresno, California, United States